ITGB6 gene encoding a protein that can regulate the integrin αvβ6 heterodimer protein expression in different status was showed that it played an important role in multiple human cancers, such as brain cancer, colon cancer and oral cancer, and related to the clinical progression. This study is to explore the function and the mechanism of ITGB6 gene or protein in pancreatic cancer.

Material and methods:
We examined the expression of ITGB6 in pancreatic cancer using immunohistochemistry and analyzed the correlationship between the expression of ITGB6 and the clinicalpathologic features in pancreatic cancer patients. In addition, bioninformatic method was conducted to analyze the ITGB6 mRNA level in pancreatic tumor tissues compared with normal pancreatic tissues and to analyze the correlationship between high KIF23 expression and prognosis in pancreatic cancer patients. Moreover, colony formation assay, MTT assay, cell scratch, cell invasion and western blot assays in vitro and xenograph mice model in vivo were performed to analyze the effect of KIF23 on proliferation and invasion of pancreatic cancer cells.

We reported that increased expression of ITGB6 was significantly correlated with poor clinical outcome in both our clinical data and TCGA data of pancreatic cancer. Furthermore, functional assays revealed that knockdown ITGB6 in vivo and in vitro might inhibit cancer cells proliferation and the ability of invasion or migration.

Our data suggests that ITGB6 is associated with pancreatic cancer malignant progression. Hence, ITGB6 may be served as a potential target of pancreatic cancer in clinical treatmentfor future research, and further study is needed.